Terms: = Pancreatic cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p
48 results:
1. PD-1 regulation in immune homeostasis and immunotherapy.
Gao M; Shi J; Xiao X; Yao Y; Chen X; Wang B; Zhang J
Cancer Lett; 2024 Apr; 588():216726. PubMed ID: 38401888
[TBL] [Abstract] [Full Text] [Related]
2. Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome.
Minz AP; Mohapatra D; Dutta M; Sethi M; Parida D; Mohapatra AP; Mishra S; Kar S; Sasmal PK; Senapati S
Cancer Immunol Immunother; 2023 Dec; 72(12):4261-4278. PubMed ID: 37926727
[TBL] [Abstract] [Full Text] [Related]
3. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
[TBL] [Abstract] [Full Text] [Related]
4. Nickel Complexes Bearing ONS Chelating Ligands: A Promising Contender for In Vitro Cytotoxicity Effects on Human pancreatic cancer MIA-PaCa-2 Cells.
Tanwar D; Kaur T; Kumar R; Ahluwalia D; Sharma D; Kumar U
ACS Appl Bio Mater; 2023 Jan; 6(1):134-145. PubMed ID: 36599051
[TBL] [Abstract] [Full Text] [Related]
5. B7 Family Members in pancreatic Ductal Adenocarcinoma: Attractive Targets for cancer Immunotherapy.
Chen X; Li J; Chen Y; Que Z; Du J; Zhang J
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499340
[TBL] [Abstract] [Full Text] [Related]
6. nc-RNA-mediated high expression of CDK6 correlates with poor prognosis and immune infiltration in pancreatic cancer.
Zhao YX; Xu BW; Wang FQ; Jiang FY; Xu JW; Yu DX
Cancer Med; 2023 Feb; 12(4):5110-5123. PubMed ID: 36457244
[TBL] [Abstract] [Full Text] [Related]
7. Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context in pancreatic ductal adenocarcinoma.
Chen X; Ma H; Mo S; Yu S; Lu Z; Chen J
Front Immunol; 2022; 13():1027459. PubMed ID: 36325339
[TBL] [Abstract] [Full Text] [Related]
8. FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer.
Davidson C; Taggart D; Sims AH; Lonergan DW; Canel M; Serrels A
Br J Cancer; 2022 Nov; 127(10):1893-1905. PubMed ID: 36138073
[TBL] [Abstract] [Full Text] [Related]
9. Hetero-bivalent agents targeting FAP and PSMA.
Boinapally S; Lisok A; Lofland G; Minn I; Yan Y; Jiang Z; Shin MJ; Merino VF; Zheng L; Brayton C; Pomper MG; Banerjee SR
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4369-4381. PubMed ID: 35965291
[TBL] [Abstract] [Full Text] [Related]
10. Implications of PD-1, Tim-3, and TIGIT Expression for cancer Immunity and pancreatic cancer Prognosis.
Nakayama C; Tanoue K; Idichi T; Shimomura H; Kita Y; Hozaka Y; Shinden Y; Matsushita D; Nakajo A; Arigami T; Mataki Y; Kurahara H; Ohtsuka T
Anticancer Res; 2022 Jul; 42(7):3373-3380. PubMed ID: 35790289
[TBL] [Abstract] [Full Text] [Related]
11. Expression and Prognostic Value of B7 Family Immune Checkpoints in pancreatic Neuroendocrine Tumors.
Mo S; Zong L; Chen X; Ban X; Li M; Lu Z; Yu S; Chen J
Arch Pathol Lab Med; 2023 Feb; 147(2):193-201. PubMed ID: 35671167
[TBL] [Abstract] [Full Text] [Related]
12. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.
Zhang Y; Chen X; Mo S; Ma H; Lu Z; Yu S; Chen J
J Pathol Clin Res; 2022 May; 8(3):257-267. PubMed ID: 35037417
[TBL] [Abstract] [Full Text] [Related]
13. Loss of adipose tissue or skeletal muscle during first-line gemcitabine/nab-paclitaxel therapy is associated with worse survival after second-line therapy of advanced pancreatic cancer.
Miki M; Lee L; Hisano T; Sugimoto R; Furukawa M
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e297-e305. PubMed ID: 34818466
[TBL] [Abstract] [Full Text] [Related]
14. Serum Soluble PD-L1, PD-L2, and B7-H5 as Potential Diagnostic Biomarkers of Human pancreatic cancer.
Wu W; Xia X; Cheng C; Niu L; Wu J; Qian Y
Clin Lab; 2021 Jun; 67(6):. PubMed ID: 34107622
[TBL] [Abstract] [Full Text] [Related]
15. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.
de Mestier L; Lamarca A; Hernando J; Zandee W; Alonso-Gordoa T; Perrier M; Walenkamp AM; Chakrabarty B; Landolfi S; Van Velthuysen MF; Kats-Ugurlu G; Caminoa A; Ronot M; Manoharan P; Garcia-Alvarez A; Brabander T; García Gómez-Muriel MI; Cadiot G; Couvelard A; Capdevila J; Pavel ME; Cros J
Endocr Relat Cancer; 2021 Jun; 28(8):549-561. PubMed ID: 34061764
[TBL] [Abstract] [Full Text] [Related]
16. Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in pancreatic cancer.
Gupta VK; Sharma NS; Durden B; Garrido VT; Kesh K; Edwards D; Wang D; Myer C; Mateo-Victoriano B; Kollala SS; Ban Y; Gao Z; Bhattacharya SK; Saluja A; Singh PK; Banerjee S
Cancer Res; 2021 Aug; 81(15):4001-4013. PubMed ID: 33990397
[TBL] [Abstract] [Full Text] [Related]
17. CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer.
Chen S; Yang C; Wang ZW; Hu JF; Pan JJ; Liao CY; Zhang JQ; Chen JZ; Huang Y; Huang L; Zhan Q; Tian YF; Shen BY; Wang YD
J Hematol Oncol; 2021 Apr; 14(1):60. PubMed ID: 33849617
[TBL] [Abstract] [Full Text] [Related]
18. Advanced breast cancer with cachexia: A case report.
Liu N; Li S; Jia J; Qiao Y; Li Y
Medicine (Baltimore); 2021 Jan; 100(4):e24397. PubMed ID: 33530236
[TBL] [Abstract] [Full Text] [Related]
19. Development and validation of a pancreatic cancer risk model for the general population using electronic health records: An observational study.
Appelbaum L; Cambronero JP; Stevens JP; Horng S; Pollick K; Silva G; Haneuse S; Piatkowski G; Benhaga N; Duey S; Stevenson MA; Mamon H; Kaplan ID; Rinard MC
Eur J Cancer; 2021 Jan; 143():19-30. PubMed ID: 33278770
[TBL] [Abstract] [Full Text] [Related]
20. Prediction of survival and recurrence in patients with pancreatic cancer by integrating multi-omics data.
Baek B; Lee H
Sci Rep; 2020 Nov; 10(1):18951. PubMed ID: 33144687
[TBL] [Abstract] [Full Text] [Related]
[Next]
